Leighann Sherry

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2630737/publications.pdf

Version: 2024-02-01

35 papers	2,413 citations	201385 27 h-index	360668 35 g-index
36 all docs	36 docs citations	36 times ranked	3025 citing authors

#	Article	IF	Citations
1	Cell Viability Assays for Candida auris. Methods in Molecular Biology, 2022, , 129-153.	0.4	3
2	Recurrent Vulvovaginal Candidiasis: a Dynamic Interkingdom Biofilm Disease of Candida and Lactobacillus. MSystems, 2021, 6, e0062221.	1.7	35
3	Interkingdom interactions on the denture surface: Implications for oral hygiene. Biofilm, 2019, 1, 100002.	1.5	15
4	Candida auris exhibits resilient biofilm characteristics inÂvitro: implications for environmental persistence. Journal of Hospital Infection, 2019, 103, 92-96.	1.4	59
5	Impact of frequency of denture cleaning on microbial and clinical parameters â€“ a bench to chairside approach. Journal of Oral Microbiology, 2019, 11, 1538437.	1.2	20
6	Surface disinfection challenges for Candida auris: an in-vitro study. Journal of Hospital Infection, 2018, 98, 433-436.	1.4	84
7	The comparative efficacy of antiseptics against Candida auris biofilms. International Journal of Antimicrobial Agents, 2018, 52, 673-677.	1.1	67
8	Transcriptome Assembly and Profiling of Candida auris Reveals Novel Insights into Biofilm-Mediated Resistance. MSphere, 2018, 3, .	1.3	151
9	Gaining Insights from Candida Biofilm Heterogeneity: One Size Does Not Fit All. Journal of Fungi (Basel, Switzerland), 2018, 4, 12.	1.5	36
10	The application of phenotypic microarray analysis to anti-fungal drug development. Journal of Microbiological Methods, 2017, 134, 35-37.	0.7	3
11	Implications of Antimicrobial Combinations in Complex Wound Biofilms Containing Fungi. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	31
12	Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients Are Heterogeneous and Insensitive to Fluconazole. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	66
13	Tolerance of Pseudomonas aeruginosa in in-vitro biofilms to high-level peracetic acid disinfection. Journal of Hospital Infection, 2017, 97, 162-168.	1.4	42
14	Biofilm-Forming Capability of Highly Virulent, Multidrug-ResistantCandida auris. Emerging Infectious Diseases, 2017, 23, 328-331.	2.0	296
15	Candida albicans biofilm heterogeneity does not influence denture stomatitis but strongly influences denture cleansing capacity. Journal of Medical Microbiology, 2017, 66, 54-60.	0.7	22
16	Viable Compositional Analysis of an Eleven Species Oral Polymicrobial Biofilm. Frontiers in Microbiology, 2016, 7, 912.	1.5	47
17	A Prospective Surveillance Study of Candidaemia: Epidemiology, Risk Factors, Antifungal Treatment and Outcome in Hospitalized Patients. Frontiers in Microbiology, 2016, 7, 915.	1.5	60
18	Development and characterisation of a novel three-dimensional inter-kingdom wound biofilm model. Biofouling, 2016, 32, 1259-1270.	0.8	34

#	Article	IF	Citations
19	Integrating Candida albicans metabolism with biofilm heterogeneity by transcriptome mapping. Scientific Reports, 2016, 6, 35436.	1.6	39
20	Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infectionâ€"Scotland, 2012â€“2013. Clinical Microbiology and Infection, 2016, 22, 87-93.	2.8	188
21	In Vitro Effect of Porphyromonas gingivalis Methionine Gamma Lyase on Biofilm Composition and Oral Inflammatory Response. PLoS ONE, 2016, 11, e0169157.	1.1	10
22	New strategic insights into managing fungal biofilms. Frontiers in Microbiology, 2015, 6, 1077.	1.5	28
23	PolymicrobialCandidabiofilms: friends and foe in the oral cavity. FEMS Yeast Research, 2015, 15, fov077.	1.1	76
24	Biofilms formed by Candida albicans bloodstream isolates display phenotypic and transcriptional heterogeneity that are associated with resistance and pathogenicity. BMC Microbiology, 2014, 14, 182.	1.3	124
25	Extracellular DNA release confers heterogeneity in Candida albicans biofilm formation. BMC Microbiology, 2014, 14, 303.	1.3	53
26	Utilising polyphenols for the clinical management of Candida albicans biofilms. International Journal of Antimicrobial Agents, 2014, 44, 269-273.	1.1	86
27	Development of an in vitroperiodontal biofilm model for assessing antimicrobial and host modulatory effects of bioactive molecules. BMC Oral Health, 2014, 14, 80.	0.8	68
28	Investigating the biological properties of carbohydrate derived fulvic acid (CHD-FA) as a potential novel therapy for the management of oral biofilm infections. BMC Oral Health, 2013, 13, 47.	0.8	35
29	Liposomal Amphotericin B Displays Rapid Dose-Dependent Activity against Candida albicans Biofilms. Antimicrobial Agents and Chemotherapy, 2013, 57, 2369-2371.	1.4	49
30	Candida albicansFungaemia following Traumatic Urethral Catheterisation in a Paraplegic Patient with Diabetes Mellitus and Candiduria Treated by Caspofungin. Case Reports in Infectious Diseases, 2013, 2013, 1-6.	0.2	6
31	Fungal Biofilm Resistance. International Journal of Microbiology, 2012, 2012, 1-14.	0.9	403
32	Antifungal, Cytotoxic, and Immunomodulatory Properties of Tea Tree Oil and Its Derivative Components: Potential Role in Management of Oral Candidosis in Cancer Patients. Frontiers in Microbiology, 2012, 3, 220.	1.5	65
33	Carbohydrate Derived Fulvic Acid: An in vitro Investigation of a Novel Membrane Active Antiseptic Agent Against Candida albicans Biofilms. Frontiers in Microbiology, 2012, 3, 116.	1.5	35
34	In Vitro Candida albicans Biofilm Induced Proteinase Activity and SAP8 Expression Correlates with In Vivo Denture Stomatitis Severity. Mycopathologia, 2012, 174, 11-19.	1.3	46
35	A Comparative In Vitro Study of Two Denture Cleaning Techniques as an Effective Strategy for Inhibiting Candida albicans Biofilms on Denture Surfaces and Reducing Inflammation. Journal of Prosthodontics, 2012, 21, 516-522.	1.7	31